Affiliation: Stanford University
- The treatment outcome for adult patients with Ewing's sarcomaKristen N Ganjoo
Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Curr Oncol Rep 15:372-7. 2013..In this article, we will review the primary treatment for adult patients with Ewing's sarcoma, both for localized and metastatic disease. The prognostic factors in adult patients with EWS will also be reviewed. ..
- The prognostic value of tumor-associated macrophages in leiomyosarcoma: a single institution studyKristen N Ganjoo
Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA, 94305, USA
Am J Clin Oncol 34:82-6. 2011..The purpose of this study is to evaluate the outcome of patients with LMS from a single institution according to the number of TAMs evaluated through 3 CSF1 associated proteins...
- New developments in targeted therapy for soft tissue sarcomaKristen N Ganjoo
Stanford University, 269 Campus Drive, Stanford, CA 94305, USA
Curr Oncol Rep 12:261-5. 2010....
- A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcomaKristen N Ganjoo
Stanford University Medical Center, Stanford, Calif, USA
Oncology 80:50-6. 2011..Patients and..
- Current and emerging pharmacological treatments for gastrointestinal stromal tumourKristen N Ganjoo
Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, Stanford, California, USA
Drugs 71:321-30. 2011..The duration of adjuvant therapy is currently under evaluation; however, it is possible that these patients would need to continue therapy indefinitely...
- Antiangiogenesis agents in the treatment of soft tissue sarcomasKristen Ganjoo
Division of Oncology, Stanford University, Palo Alto, CA, USA
Cancer 116:1177-83. 2010..In addition, the authors conducted an in-depth review of the results from using key antiangiogenesis agents in the treatment of STS...
- Trabectedin: an anticancer drug from the seaKristen N Ganjoo
Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Expert Opin Pharmacother 10:2735-43. 2009..Trabectedin (ET-743) is an anticancer agent originally isolated from Ecteinascidia turbinata, a marine organism...
- The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patientsKristen N Ganjoo
Division of Oncology, Stanford University, Stanford, CA, USA
J Cancer Res Clin Oncol 134:381-7. 2008..This is a single institution retrospective study evaluating the role of angiogenesis markers in the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL)...
- Non-Hodgkin lymphoma of the breastKristen Ganjoo
Department of Medical Oncology, Stanford University, Stanford, California, USA
Cancer 110:25-30. 2007..A retrospective study was done to evaluate the institutional experience in this patient population...
- Antiangiogenesis: a new approach to the treatment of lymphomaKristen Ganjoo
Department of Medicine Oncology, Stanford University, Palo Alto, CA 94304, USA
Leuk Lymphoma 48:454-5. 2007
- Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysisKristen N Ganjoo
Department of Medicine Oncology, Stanford University, CA, USA
Leuk Lymphoma 47:998-1005. 2006..In this patient population, treatment with RA-CHOP did not result in any episodes of grade 3 or 4 proteinuria, heart failure or hemorrhage. The RA-CHOP combination was generally well tolerated and safe...
- Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancerJonathan W Riess
Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
Cancer Invest 30:231-5. 2012..268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients...
- Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndromeEve Henry
Department of Medicine, Stanford University, Stanford, California, USA
J Natl Compr Canc Netw 10:939-42. 2012....
- Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth FactorRondeep Brar
Department of Internal Medicine, Stanford University Medical Center, Stanford, Calif, USA
Case Rep Oncol 2:242-250. 2009..CONCLUSION: Angiosarcoma of the breast is an aggressive malignancy with a propensity for both local recurrence and distant metastases. Angiogenesis inhibition may represent a novel therapeutic modality in this rare, vascular malignancy...
- Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter StudyBrad S Kahl
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
Cancer 116:106-14. 2010..Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma...
- A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancerChristelle Clément-Duchêne
Division of Oncology, Department of Medicine, Department of Biostatistics, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
J Thorac Oncol 5:1821-5. 2010..This study was designed to evaluate toxicities and efficacy of gemcitabine/carboplatin/bevacizumab...
- Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)Kristen Ganjoo
Stanford University, Stanford, CA, USA
Leuk Lymphoma 55:768-72. 2014..Studies of novel therapeutics are needed for this patient population, whose clinical outcome remains poor...
- Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemiaArthur E Frankel
Department of Medicine, Scott and White Hospital, Temple, Texas 76508, USA
Cancer 106:2158-64. 2006....
- 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphomaAndrei Iagaru
Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Mol Imaging Biol 12:198-203. 2010..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...